A 10-Year Retrospective Pilot Study of Parenteral Diphenhydramine Use in Home Infusion Patients
Infusion Journal · 2022
DOI: 10.70776/gwkx4337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infusion Journal, 2022. Verfasst von Mary Beth Letourneau und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Patients who administer chronic parenteral diphenhydramine are at risk of developing behavioral issues that may represent misuse or abuse. The purpose of this study was to assess potential risk factors and comorbidities for medication noncompliance in the home infusion patient population prescribed parenteral diphenhydramine.
Methods
The study was a retrospective review of the patient population prescribed parenteral diphenhydramine from 2010 to 2020. Data collected from the electronic health record included age, gender, race, indication, type of specialty practice prescribing, duration of therapy, prior history of oral diphenhydramine use, reason for discontinuation, comorbidities, and concomitant medications. Comorbidities assessed included chronic pain, tobacco use, alcohol use, psychiatric disorders, venous access device infections, history of venous thromboembolism, documented overdoses, and history of drug abuse.
Results
Between 2010 and 2020, 101 patients were prescribed scheduled parenteral diphenhydramine. After exclusions, the study group contained 76 patients who met the inclusion criteria. Noncompliance was documented in 27 patients (35.5%). Noncompliance was associated with a diagnosis of mast cell disorder (25.9%) and nausea and vomiting (44.4%). Comorbidities associated with noncompliance included chronic pain (88.9%) and psychiatric disorders. The age range for the compliant group was 20-69 and the noncompliant group was 20-49. Noncompliance was more common in females than males in the study.
Conclusion
The analysis of this patient population supports patients showing signs of parenteral diphenhydramine misuse tend to have higher rate of comorbidities associated with substance use disorders when the duration of therapy was 3 months or longer. Keywords: Diphenhydramine, abuse, noncompliance, infusion, intravenous, Benadryl®
Zitieren
APA
Letourneau, M. B., Sievert, E., & MacInnis, A. (2022). A 10-Year Retrospective Pilot Study of Parenteral Diphenhydramine Use in Home Infusion Patients. Infusion Journal. https://doi.org/10.70776/gwkx4337
Vancouver
Letourneau MB, Sievert E, MacInnis A. A 10-Year Retrospective Pilot Study of Parenteral Diphenhydramine Use in Home Infusion Patients. Infusion Journal. 2022. doi:10.70776/gwkx4337
BibTeX
@article{Letourneau2022,
author = {Letourneau, Mary Beth and Sievert, Erica and MacInnis, Amy},
title = {A 10-Year Retrospective Pilot Study of Parenteral Diphenhydramine Use in Home Infusion Patients},
journal = {Infusion Journal},
year = {2022},
doi = {10.70776/gwkx4337}
}
EUVIMED